Research map: Effects of Long-Term Lobeglitazone Treatment on Renal Function and Albuminuria in Korean Patients with Type 2 Diabetes Mellitus: A Multicenter Retrospective Observational Study (LUCKY)

Back to the article

Papers in this map

  1. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial · John Dormandy · 2005 · 4156 citations · Cited by this paper
  2. Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece · 2026 · Related
  3. Diabetic Kidney Disease · Radica Z. Alicic · 2017 · 2909 citations · Cited by this paper
  4. Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response · 2026 · Related
  5. Diabetic kidney disease · Merlin C. Thomas · 2015 · 1256 citations · Cited by this paper
  6. Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category · 2026 · Related
  7. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack · Walter N. Kernan · 2016 · 1124 citations · Cited by this paper
  8. Insulin Injection Behaviors and Association with Glycemic Outcomes in Patients with Diabetes: A Real-World Survey in Spain · 2026 · Related
  9. Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis · Pantelis A. Sarafidis · 2010 · 199 citations · Cited by this paper
  10. Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review · 2026 · Related
  11. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ · Jun Young Jang · 2018 · 91 citations · Cited by this paper
  12. A Retrospective Analysis of the Clinical Characteristics and Treatment Patterns Among Individuals with Diabetes Receiving Insulin Therapy in Japan: The Insulin JP2DB Study · 2026 · Related
  13. Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial · Sin Gon Kim · 2014 · 84 citations · Cited by this paper
  14. Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study · 2026 · Related
  15. Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis · Soo Lim · 2015 · 63 citations · Cited by this paper
  16. Beyond Coverage Expansion: Exploring Persistent Barriers to CGM Utilization in the Clinical Environment · 2026 · Related
  17. Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase III clinical trial with a 28‐week extension · Sang‐Man Jin · 2015 · 51 citations · Cited by this paper
  18. Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes · 2026 · Related
  19. Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis · Wen Wang · 2017 · 46 citations · Cited by this paper
  20. Continuous Glucose Monitoring Before and After Simultaneous Pancreas–Kidney Transplantation: Insights from a Real-World Clinical Setting · 2026 · Related
  21. Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study · Sun Hwa Kim · 2015 · 32 citations · Cited by this paper
  22. A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus · Bo‐Yeon Kim · 2022 · 18 citations · Cited by this paper
  23. Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice · Kwi-Hyun Bae · 2017 · 17 citations · Cited by this paper
  24. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men · Seol Ju Moon · 2020 · 17 citations · Cited by this paper
  25. Status and trends in epidemiologic characteristics of diabetic end-stage renal disease: an analysis of the 2021 Korean Renal Data System · Kyeong Min Kim · 2024 · 13 citations · Cited by this paper
  26. Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State · Kyungho Jang · 2020 · 7 citations · Cited by this paper
  27. No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects · Yu Kyong Kim · 2021 · 7 citations · Cited by this paper
  28. Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects · Heeyoung Kim · 2023 · 6 citations · Cited by this paper
  29. Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial · Eun‐Gyoung Hong · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)